Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
16 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
GYNEZOL from Genk, company number BE1008674987, closed financial year 2025 with a result of € 0 after tax. For that financial year GYNEZOL recorded a gross margin of € 57,822 and equity of € 5,500. Compared with financial year 2024, the result moved from € 0 to € 0. Around break-even. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ 5,500
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 0
Profit after tax over the fiscal year.
€ 85,916
▲ 88% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 0.
People and assets in 2025
€ 52,213
▲ 55% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 2,852
▼ 40% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 4,418
▼ 77% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 7,277
▲ 63% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € 37,272 | € 57,822 | ▲ 55% |
| Equity | € 5,500 | € 5,500 | |
| Total debts | € 2,317,985 | € 2,851,025 | ▲ 23% |
| Cash | € 45,720 | € 85,916 | ▲ 88% |
| Balance sheet total | € 2,323,485 | € 2,856,525 | ▲ 23% |
Key figures of GYNEZOL, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to GYNEZOL?
What happened at GYNEZOL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 0. filed late Source: NBB ↗
- New establishment in Genk. KBO
- New establishment in Diepenbeek. KBO
- Jean-Christophe Schobbens became a director. NBB
- Julie Marie Peter Faes became a director. NBB
- Eva De Cuyper became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 0 profit in 2024 to € 0 profit in 2025.
Paid € 228 in corporate taxes since 2024.
A new publication or filing at GYNEZOL? We notify you, reason included.
Follow GYNEZOLDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind GYNEZOL are Jean-Christophe Schobbens, Julie Marie Peter Faes and Eva De Cuyper. Jean-Christophe Schobbens is also behind DOKTER SCHOBBENS - DOKTER REYNDERS and GyneHoeselt. Eva De Cuyper is also behind DR. DE CUYPER EVA.
Directors
According to the 2025 annual accounts
since 2024
Julie Marie Peter Faes
Director
since 2024
since 2024
Establishments
Establishment units
Physical locations of this company
Synaps Park 1
3600 Genk
Nieuwstraat 173 box B
3590 Diepenbeek
Active since 23 April 2024
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 16 companies are registered at this address.
All companies at this address →Ziekenhuis Oost-Limburg, autonome verzorgingsinstelling
Werkgroep Endovasculaire Heelkunde en Vaatdiagnostiek
DR. JAARKE VANNOOTE-GASTRO-ENTEROLOOG
€ 414,126 gross margin · 2025
Feitelijke organisatie plastische heelkunde ZOL Genk
Associatie Neurologie Ziekenhuis Oost - Limburg fv
+11 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1008.674.987
- VAT number
- BE 1008.674.987
- Registered office
- Synaps Park 1, 3600 Genk
- Names & denominations
- GYNEZOL
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 23 April 2024
- Peppol
- Active · Active since 28 Jan 2026
- Activities · NACE
Activiteiten van medisch specialisten